Company intelligence / Profile preview

Eulogiums Co. LTD.

Seoul, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Eulogiums is a South Korean biotechnology company specializing in the development of disease-modifying therapies for neurodegenerative diseases. The company leverages a proprietary platform focused on autophagy enhancement to facilitate the clearance of pathological protein aggregates, such as alpha-synuclein. Its lead program, EUL-101, is a brain-penetrant small molecule targeting Parkinson's disease and multiple system atrophy. By restoring the cell's natural waste disposal system, Eulogiums aims to halt or reverse the progression of synucleinopathies. The company was founded by Dr. Seung-Jae Lee, a leading expert in protein misfolding and neurodegeneration.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Eulogiums Co. LTD..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eulogiums Co. LTD..

Explore the full profile